Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALAFOSS-01
2024-516699-14-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label trial of AZD0022 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by AstraZeneca. Primary endpoints: Incidence and severity of adverse events and serious adverse events, Incidence of dose-limiting toxicities and 3 more. Started Apr 2025; status: completed.
02
Drugs
AZD0022
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-516699-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516699-14-00.